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M A J O R A R T I C L E
Helicobacter pylori Infection Is Associated
with Increased Expression of Macrophage Migratory
Inhibitory Factor—by Epithelial Cells, T Cells,
and Macrophages—in Gastric Mucosa
Harry Hua-Xiang Xia,1 Shiu-Kum Lam,1 Xiao-Ru Huang,1,3 Wai-Man Wong,1 Suet-Yi Leung,2 Siu-Tsan Yuen,2
Hui-Yao Lan,1,3 and Benjamin Chun-Yu Wong1
Departments of 1Medicine and 2Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong, S.A.R., China; 3Department of
Medicine, Section of Nephrology, Baylor College of Medicine, Houston, Texas
The macrophage migratory inhibitory factor (MIF) plays a pivotal role in inflammatory and immune diseases;
however, its role in gastrointestinal diseases has not been clarified. This study intended to determine the
expression of MIF, by gastric epithelial cells, T cells, and macrophages, in Helicobacter pylori–induced gastritis.
Sixty-four patients (30 males, 34 females; mean age, 47 years) referred for upper endoscopy were recruited.
Biopsy specimens from the gastric antrum and corpus were obtained for (1) detection of H. pylori and
histological examination, (2) single and double immunostaining to test for expression of MIF protein in
epithelial cells, T cells, and macrophages, and (2) in situ hybridization for expression of MIF mRNA within
the lamina propria. In mucosal specimens from each of the 2 sites, both the percentage of MIF+ epithelial
cells and the numbers of MIF mRNA+ inflammatory cells, MIF+ T cells, and MIF+ macrophages were significantly
higher in H. pylori–positive patients than in H. pylori–negative patients. Overall, the percentage of MIF+
epithelial cells and the numbers of MIF mRNA+ cells, MIF+ T cells, and MIF+ macrophages were higher in
the antrum than in the corpus. The percentage of MIF+ epithelial cells and the numbers of MIF mRNA+ cells,
MIF+ T cells, and MIF+ macrophages increased in chronic gastritis, but, in the absence of H. pylori infection,
this increase disappeared for all except MIF+ T cells. Therefore, H. pylori infection is associated with increased
expression of the MIF protein and MIF mRNA in gastric epithelial and inflammatory cells; along with other
cytokines, MIF may play a significant role in gastric inflammation related to H. pylori infection.
The macrophage migratory inhibitory factor (MIF) has
been shown to play a pivotal role in inflammatory and
immune-mediated diseases [1–15]; however, its role in
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gastrointestinal diseases has rarely been investigated
[16–19]. Our recent study using a rodent gastric-ulcer
model has demonstrated that MIF is markedly up-reg-
ulated during acute ulceration, which is associated with
the accumulation of macrophages at the sites of in-
flammation [17]. Blockade of MIF by the neutralizing
anti-MIF antibody significantly inhibits both macro-
phage accumulation and up-regulation of MIF, as well
as tumor-necrosis factor a (TNF-a), inducible nitric
oxide synthase (iNOS), and intercellular adhesion mol-
ecule 1 (ICAM-1), an effect that indicates an important
role for MIF in the pathogenesis of gastric ulceration
[17].
Helicobacter pylori is a bacterium that colonizes the
human stomach and causes gastric inflammation and
peptic ulcer disease, and it is believed to play an im
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Figure 1. Expression of MIF mRNA in inflammatory and epithelial cells in the mucosa of the gastric antrum. In situ hybridization demonstrates
weak expression in Helicobacter pylori–negative normal mucosa (A) and strong cytoplasmic or perinuclear expression (darker areas) in H. pylori–
positive mucosa (B). Original magnification, 100.
portant role in the development of gastric carcinogenesis [20–
24]. H. pylori infection causes gastric mucosal damage by pro-
ducing many virulence factors, such as urease, lipopolysaccharide
(LPS), a vacuolating cytotoxin (VacA), and phospholipases; by
promoting inflammatory and immune responses; and by re-
leasing large amounts of chemokines, cytokines, and reactive
oxygen metabolites [18]. These changes subsequently affect the
secretion of gastric acid and ascorbic acid, as well as cell apoptosis
and proliferation [22, 24]. Reactive oxygen metabolites, hypoch-
lorhydria, low levels of ascorbic acid, and imbalanced cell ap-
optosis and proliferation all contribute to the increased risk of
the development of gastric cancer in a proportion of susceptible
individuals [22, 24]. We hypothesize that H. pylori infection may
result in gastric inflammation and ulceration, at least partly via
an MIF-mediated pathway. Therefore, the intention of this pro-
ject was to determine the expression of MIF in the gastric mucosa
in patients with and without H. pylori infection.
PATIENTS AND METHODS
Patients and gastric-biopsy specimens. Sixty-four patients (30
males, 34 females; mean ageSD, years), referred for47 16
upper endoscopy and diagnosed as having nonulcer dyspepsia,
were recruited for the study. At endoscopy, 4 biopsy specimens—
3 from the antrum and 1 from the corpus—were obtained; 1 of
the antral-biopsy specimens was used for an in-house rapid-
urease test; the other 3 biopsy specimens were fixed in formalin
and embedded in paraffin, for histological examinations, im-
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Figure 2. Expression of MIF mRNA in the antrum and in the corpus, with (+) or without () Helicobacter pylori infection and with (+) or without
() histological chronic gastritis, as determined by in situ hybridization. * , compared with patients either without H. pylori infection or withoutP ! .001
chronic gastritis. The vertical line extending from the top of each bar denotes the standard error of the mean.
munohistochemistry, and in situ hybridization. All patients gave
informed written consents, and this project was approved by the
Ethics Committee of The University of Hong Kong.
Detection of H. pylori infection and histological exami-
nations. The in-house rapid-urease test solution was pre-
pared daily by dissolving 0.5 g of urea into 10 mL of distilled
water and mixing the solution with 10 drops of 0.1% phenol
red as a pH indicator. In the detection of H. pylori, this test
has been shown to have a sensitivity of 99% and a specificity
of 100% [25]. Sections (4 mm) of the paraffin-embedded tissue
were stained with hematoxylin and eosin. Histological changes
and Helicobacter-like organisms were examined. Patients were
defined to be H. pylori positive if positive results were obtained
by both rapid-urease test and histology (i.e., Helicobacter-like
organisms were present) or by histology, at both the gastric
antrum and the gastric corpus. Patients were defined to be H.
pylori negative if the results of all tests were negative. Patients
positive by only the rapid-urease test or by histology at only a
single site were excluded from this study. The updated Syd-
ney system was adapted to assess the severity and activity of
gastric inflammation [21]. Chronic gastritis was considered to
be present when there was an infiltration of chronic inflam-
matory cells (i.e., mononuclear cells); it was classified as grade
1 (mild), grade 2 (moderate), or grade 3 (marked), according
to the number of infiltrating cells. The activity of gastritis (i.e.,
the presence of neutrophil polymorphs on a background of
chronic inflammation) also was assessed.
Immunohistochemistry and in situ hybridization. Biopsy
specimens from the antrum and corpus of all patients were
subjected to both a single-immunostaining (for epithelial cells)
and a double-immunostaining (for activated T cells and mac-
rophages) technique, as described elsewhere [17]. For the single
immunostaining, sections were dewaxed, labeled by use of
mouse anti-murine MIF monoclonal antibody (mAb)—which
recognizes recombinant mouse and human MIF by Western
blotting, as specified elsewhere [1, 3, 11, 17]—and developed
by use of 3, 3-diaminobenzine (Sigma), which produced a
brown-colored product. For the double immunostaining, sec-
tions were dewaxed, labeled by use of a mouse anti–human
monocyte/macrophage (i.e., KP1) mAb or T cell (i.e., CD45RO)
mAb (all from Transduction Lab), and developed by use of 3,
3-diaminobenzine, which produced a brown-colored product.
After being microwaved, sections were labeled by use of mouse
anti-MIF mAb that used a 3-layer mouse alkaline phosphatase/
anti–alkaline phosphatase complex and, finally, were developed
by use of Fast Blue BB Base (Sigma), which produced a blue-
colored product [17]. For expression of MIF in gastric epithelial
cells, the percentage of the total epithelial cells (1300) that were
MIF+ in 5 randomly selected fields was calculated. For the ex-
pression of MIF protein in the inflammatory cells, the numbers,
per square millimeter, of T cells, MIF+ T cells, macrophages,
and MIF+ macrophages in the lamina propria were counted
and the percentages of T cells and macrophages that were MIF+
were calculated [17].
In situ hybridization was performed by use of a microwave-
based method, as described in our previous study [17]. Any
cells positively stained within the lamina propria were counted
as MIF mRNA+ cells, and the number of MIF mRNA+ cells per
square millimeter was calculated. These cells consisted mostly
of glandular epithelial cells and infiltrated inflammatory cells.
Statistic analysis. Data were expressed as mean  SEM.
The SPSS system (version 10.0) was used to perform statistical
analysis. Independent-samples t test, the Mann-Whitney U test,
or 1-way analysis of variance (ANOVA) was used to determine
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Figure 3. Expression of MIF in epithelial cells in the mucosa of the gastric antrum. Single immunostaining demonstrates weak expression in
Helicobacter pylori–negative normal gastric mucosa (A) and strong cytoplasmic or perinuclear expression (brown color, denoted by arrows) in H. pylori–
positive mucosa (B). Original magnification, 100.
the differences of the numeric variables. A paired-samples t test
or a Wilcoxon signed-ranks test was used to determine the
numeric-variables differences between the antrum and the cor-
pus. All P values calculated were 2-tailed. The alpha level of
significance was set at .P ! .05
RESULTS
Expression of MIF mRNA in gastric mucosa, in relation to H.
pylori infection and chronic gastric inflammation. Of the
64 patients in the present study, 45 were positive for H. pylori
infection and 19 were negative. Significant (i.e., moderate or
marked) chronic inflammation in the antrum was seen in al-
most all (93.4%) of the H. pylori–positive patients but in none
of the H. pylori–negative patients, and, in the corpus too it was
more common in H. pylori–positive patients than in H. pylori–
negative patients (53.3% vs. 2.2%).
In H. pylori–negative normal mucosa, the expression of MIF
mRNA was weak and mostly within the glandular epithelial
cells (figure 1A). However, H. pylori infection was associated
with a strong cytoplasmic or perinuclear expression of MIF
mRNA in both the glandular epithelial cells and the infiltrated
inflammatory cells (figure 1B).
In general, the number of MIF mRNA+ cells in the antrum
was significantly higher than that in the corpus ( /1814 348
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Figure 4. Expression of MIF in the antrum and in the corpus, with (+) or without () Helicobacter pylori infection and with (+) or without ()
histological chronic gastritis, as determined by single immunostaining. * , compared with patients either without H. pylori infection or withoutP ! .001
chronic gastritis. The vertical line extending from the top of each bar denotes the standard error of the mean.
mm2 vs. /mm2; ). Both in the antrum and1063.9 185 P ! .001
in the corpus, the number of MIF mRNA+ cells was significantly
higher when H. pylori infection and chronic gastritis were present
(figure 2). Moreover, the increased expression of MIF mRNA+
cells was significantly associated with severity of chronic gastritis,
in both the antrum ( /mm2 in mild, /mm2830 10 2780 264
in moderate, and /mm2 in marked gastritis;3084 552 P !
, ANOVA) and the corpus ( /mm2 in mild,.001 1163 221
/mm2 in moderate, and /mm2 in marked1738 328 2080 324
gastritis; , ANOVA). However, when H. pylori–positiveP ! .001
patients were excluded from the analysis, the number of MIF
mRNA+ cells was not significantly different between patients with
and patients without chronic gastritis, in both the antrum
( /mm2 vs. /mm2) and the corpus (438 177 830 10 344
/mm2 vs. /mm2). Expression of MIF mRNA was not149 630 30
associated with the density of H. pylori or with the activity of
chronic gastritis (data not shown).
Expression of MIF protein in gastric epithelial cells, in re-
lation to H. pylori infection and inflammation. MIF+ gastric
epithelial cells can be identified by the immunostaining technique
(figure 3A and 3B). In H. pylori–negative patients, the percentage
of MIF+ epithelial cells in the antrum and in the corpus was
and , respectively. When H. pylori11.6% 1.0% 10.6% 1.1%
infection was present, the percentage of MIF+ epithelial cells was
significantly higher at both sites, with the increase in the antrum
( ) being more prominent than that in the corpus42.4% 4.5%
( ) (figure 4). The increased expression of MIF in37.9% 3.9%
epithelial cells was significantly associated with severity of chronic
gastritis, in the antrum ( in mild,12.7% 1.4% 34.6%
in moderate, and in marked gastritis;2.8% 56.3% 6.7% P !
, ANOVA) and in the corpus ( in mild,.001 22.0% 4.4%
in moderate, and in marked gas-35.0% 6.0% 50.1% 2.0%
tritis; , ANOVA). However, when H. pylori–positive pa-P ! .001
tients were excluded from the analysis, the percentage of MIF+
epithelial cells in the antrum and the corpus was not significantly
different in patients with and patients without chronic gastritis,
in both the antrum ( vs. ) and the10.4% 1.5% 12.3% 1.2%
corpus ( vs. ). There was no asso-10.0% 1.8% 10.9% 1.4%
ciation between the increased expression of MIF in epithelial cells
and the density of H. pylori infection and the activity of gastritis
(data not shown).
Expression of MIF protein in T cells and macrophages in
gastric mucosa, in relation to H. pylori infection and inflam-
mation. MIF+ activated T cells and MIF+ macrophages can be
identified by use of the double-immunostaining technique(figure
5A and 5B). Overall, the numbers of total T cells and of mac-
rophages were significantly higher in the antrum than in the
corpus (tables 1 and 2). The increased expression of MIF protein
in T cells and macrophages when H. pylori infection was present
correlated well with the increased expression of MIF mRNA in
the gastric mucosa in both the antrum and the corpus (all P !
, as determined by use of bivariate correlation)..001
In both the antrum and the corpus, the numbers of total T
cells and total macrophages were significantly higher in H. py-
lori–positive patients than in H. pylori–negative patients (tables
1 and 2): in the antrum, the percentage of MIF+ T cells and
MIF+ macrophages was significantly higher in H. pylori–positive
patients than in H. pylori–negative patients (table 1); in the
corpus, the percentage of MIF+ macrophages was also signifi-
cantly higher in H. pylori–positive patients than in H. pylori–
negative patients, but the percentage of MIF+ T cells was not
(table 2). However, in both the antrum and the corpus, the
increase in the percentages of MIF+ T cells and MIF+ macro-
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Figure 5. Representative examples of double immunostaining for expression of MIF protein by activated T cells and macrophages in mucosa of
the gastric antrum. Strong cytoplasmic expression of MIF+ CD45RO (brown/blue color) (A) and of MIF+ KP1 (brown/blue color) (B) is seen in Helicobacter
pylori–positive mucosa. Original magnification, 400.
phages was independent of the density of H. pylori infection
(tables 1 and 2).
Similarly, the numbers of total T cells, MIF+ T cells, total
macrophages, and MIF+ macrophages were significantly higher
in patients with chronic gastritis in the antrum and the corpus
than in patients with normal gastric mucosa. In addition, the
increased numbers of cells correlated well with the severity of
chronic gastritis (tables 1 and 2). When chronic gastritis was
present, the percentage of MIF+ macrophages, but not the per-
centage of MIF+ T cells, was significantly increased and correlated
with the severity (tables 1 and 2); however, when H. pylori–
positive patients were excluded from the analysis, only MIF+ T
cells in the antrum increased significantly when chronic gastritis
was present, compared with what was seen for normal gastric
mucosa ( /mm2 vs. /mm2; ).432.3 39.6 693.2 49.5 Pp .03
DISCUSSION
The present study clearly demonstrates that H. pylori infection
is associated with increased expression of MIF in gastric epi-
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Table 1. Expression of MIF protein by T cells and macrophages in the gastric antrum, in relation to Helicobacter pylori infection
and histological chronic gastritis.
Category (no. of patients)
T cells, no. of cells/mm2
No. of MIF+
cells/total no.
of T cells, %
Macrophages,
no. of cells/mm2
No. of MIF+
cells/total no. of
macrophages, %Total MIF+ Total MIF+
Entire sample (64) 1682  131 1245  107 72.1  1.5 849  97 479  60 46.8  2.4
H. pylori infection at corresponding site
Positive
Small number (10) 1869  286 1432  266 74.6  4.7 892  178 519  156 52.3  5.3
Moderate number (8) 1793  221 1394  217 76.5  3.8 1199  230 665  110 56.9  2.7
Large number (27) 2220  239 1673  188 74.9  2.0 1252  153 732  93 56.0  3.2
Positive overall (45) 2026  162a 1570  132a 75.1  1.7b 1167  109a 675  68a 55.4  2.2a
Negative (19) 879  58 611  45 68.3  1.9 132  6 36  3 27.5  2.5
Chronic gastritis at corresponding site
Present
Mild (16) 1178  150 856  140 69.6  2.4 228  53 85  30 30.9  3.7
Moderate (21) 1905  152 1435  137 74.8  2.9 1091  130 632  93 54.7  3.3
Marked (21) 2238  303c 1706  236c 75.7  2.0 1322  188d 775  107d 57.7  3.1d
Present overall (58) 1824  139e 1373  114 73.7  1.5 927  102e 527  61e 49.0  2.6e
Absent (6) 639  56 432  40 67.7  2.6 128  6 34  3 26.8  2.2
NOTE. Data are mean  standard error of the mean. MIF, macrophage migratory inhibitory factor.
a .P ! .001
b , compared with H. pylori–negative cases.Pp .02
c , as determined by use of 1-way ANOVA for cases with different severity of chronic gastritis.P ! .01
d , as determined by use of 1-way ANOVA for cases with different severity of chronic gastritis.P ! .001
e , compared with cases without chronic gastritis.P ! .001
thelial cells. H. pylori infection is also associated with increased
expression of MIF in T cells and in macrophages in the lamina
propria.
Recent studies have shown that MIF is a proinflammatory
cytokine that is constitutively expressed, stored in a preformed
manner in cytoplasm, and released into circulation when stim-
ulated [7, 8]. It is known that preformed MIF protein is present
in both resting macrophages and monocytes [26], indicating
that the macrophage is not only a target but also a source of
MIF in vivo [1–9]. Similarly, resting T cells and epithelial cells
also contain preformed MIF [1–3, 6, 11, 14, 26]. Once released,
MIF functions as a cytokine to promote recruitment of neu-
trophils and macrophages and their migration to the site of
inflammation [27–29]. MIF also causes cell activation and ex-
pression of inflammatory cytokines—including IL-1, IFN-g,
and TNF-a—and adhesion molecules—including ICAM-1 and
vascular cell adhesion molecule-1 (VCAM-1)—and plays a role
in endotoxemia, septic shock, and inflammatory and immune
diseases [1–17, 26, 28, 29]. Despite accumulated evidence that
MIF plays an important role in inflammation and immune
responses, studies of the role that it plays in the gastrointestinal
diseases are rare [16–19]. Murakami et al. observed that, in the
colonic mucosa, both the level of MIF in sera and the expression
of MIF were higher in patients with ulcerative colitis than in
normal control subjects [16]. Then they found that mature
dendritic cells in colonic mucosa of patients with ulcerative
colitis are a main source of MIF, which in turn induces pro-
duction of IL-1 and IL-8 by monocytes and dendritic cells [30].
We applied a double-staining technique to simultaneously de-
tect, in gastric mucosa, activated T cells and macrophages and
expression of MIF in these cells, because previous studies have
shown that activated T cells and macrophages/monocytes are
the major cellular sources of MIF [17, 31]. Moreover, we ob-
served that MIF is constitutively expressed, albeit weakly, in
normal gastric epithelial cells but is significantly increased in
H. pylori infection. Similarly, our previous animal study dem-
onstrated weak expression of MIF in normal rat gastric mucosa
[17]. Recently, Maaser et al. reported that both MIF mRNA
and MIF protein were abundantly expressed in human gastric
epithelial cells in vivo and in gastric cancer cells in vitro, al-
though H. pylori status and mucosal histology were not revealed
and a gastric-cancer cell line was used in their study [18].
Therefore, we hypothesize that colonization of H. pylori in the
stomach directly stimulates the gastric epithelial cells to release
MIF, which then promotes local infiltration of inflammatory
cells, including T- and B-lymphocytes and macrophages, by
inducing the chemokine IL-8, as has been seen in septic-shock
and inflammatory lung diseases [27–31], resulting in the pro-
duction of inducible nitrite oxide synthase (iNOS) and cyto-
toxic cytokines such as TNF-a, IFN-g, and ICAM-1. Conse-
quently, activated T cells and macrophages release a large
amount of MIF. In the presence of chronic H. pylori infection,
this cycle continues, which contributes to more-severe inflam-
mation and to gastric injury such as erosion and ulcerations.
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Table 2. Expression of MIF protein by T cells and macrophages in the gastric corpus, in relation to Helicobacter pylori infection
and histological chronic gastritis.
Category (no. of patients)
T cells, no. of cells/mm2
No. of MIF+
cells/total no.
of T cells, %
Macrophages,
no. of cells/mm2
No. of MIF+
cells/total no. of
macrophages, %Total MIF+ Total MIF+
Entire sample (64) 1171  98 786  76 63.1  1.7 482  59 254  39 40.5  2.5
H. pylori infection at corresponding site
Positive
Small number (19) 1131  127 756  112 62.0  3.1 520  96 308  81 48.0  4.7
Moderate number (14) 1607  223 1097  162 66.9  3.0 712  107 382  73 49.4  3.8
Large number (12) 1588  285 1090  227 64.8  3.8 777  164 385  89 47.5  4.2
Positive overall (45) 1392  117a 944  92a 64.2  1.9 647  69a 351  47a 48.3  2.5a
Negative (19) 580  58 360  44 60.4  2.3 75  5 16  2 21.1  2.7
Chronic gastritis at corresponding site
Present
Mild (30) 1075  133 683  92 60.5  2.2 384  80 186  48 36.6  3.4
Moderate (18) 1387  157 984  139 67.3  3.2 668  94 388  82 50.8  4.3
Marked (6) 1968  408b 1424  348b 70.6  3.3 1026  218c 557  75c 57.3  4.0c
Present overall (54) 1263  105d 853  82d 63.7  1.7 542  65d 290  43d 43.4  2.7d
Absent (10) 518  80 311  43 59.72.2 101  30 27  12 22.2  3.8
NOTE. Data are mean  standard error of the mean. MIF, macrophage migratory inhibitory factor.
a , compared with H. pylori–negative patients.P ! .001
b , as determined by use of 1-way ANOVA for cases with different severity of chronic gastritis.P ! .05
c .P ! .01
d , compared with cases without chronic gastritis.P ! .001
Supporting this hypothesis is the recent report by de Jong et
al. that MIF-deficient mice failed to develop colitis, whereas
restoration of expression of MIF in MIF-deficient mice resulted
in renewed colitis, indicating that the development of chronic
colitis in mice is dependent on MIF [19]. Although chronic
colitis and chronic gastritis are 2 different diseases, they share
a similar pathogenesis—interplay between the mucosal im-
mune system and gastrointestinal bacteria [32].
The expression of both MIF protein and MIF mRNA was
significantly higher in the antrum than in the corpus, especially
when H. pylori infection was present; moreover, when the latter
was present, the percentage of MIF+ T cells was significantly
increased in the antrum but not in the corpus, although the
percentages of MIF+ gastric epithelial cells and macrophages
were increased in both the antrum and the corpus. These find-
ings imply that H. pylori–induced chronic inflammation is more
severe in the antrum than in the corpus. Indeed, the present
study and previous histological studies have observed that
chronic gastritis is predominantly present in the antrum [21,
33]. More important, gastric cancer and precancerous lesions—
including gastric atrophy, intestinal metaplasia, and dysplasia—
occur more frequently in the antrum than in the corpus [33–
36]. Therefore, it has been postulated that increased expression
of MIF in the antrum, by inflammatory cells as well as by gastric
epithelial cells, may be one of the factors that contribute to the
progress of chronic gastritis to precancerous lesions and gastric
cancer [17, 18]. In fact, studies have shown that MIF may also
contribute to multiple aspects of tumor progression and neo-
plasia, by modulating cell proliferation, tumor angiogenesis,
and tumor-suppressor activity [37]. Recently, there has been
evidence that MIF may be the factor that links inflammation
to carcinogenesis, [38, 39]. We hypothesize that MIF may be
one of the initiating factors that “switch” chronic inflammation
to carcinogenesis in the stomach, by affecting the balance be-
tween apoptosis and cell proliferation; however, this hypothesis
needs to be tested in further studies.
MIF has been shown to exhibit antiapoptotic activities in
various cell lines, most likely by inhibiting the tumor-sup-
pressor gene, p53 [38–40]; however, it is unknown how MIF
affects apoptosis in H. pylori–infected gastric epithelial cells.
Previous studies have consistently demonstrated that H. pylori
infection induces apoptosis, which may play an important role
in H. pylori–induced gastric carcinogenesis [22, 41]; so MIF
may have little impact on H. pylori–induced apoptosis in the
early stage of gastric carcinogenesis. Although both p53 ex-
pression and apoptosis are increased in H. pylori–infected gas-
tric epithelium [22, 42, 43], numerous studies have suggested
that H. pylori–induced apoptosis is mediated by multiple eu-
karyotic signaling cascades that are not dependent on increased
p53 levels [41, 44–47]. More recently, Suzuki et al. have ob-
served that gastric epithelial apoptosis and proliferation in-
creased in both wild-type and p53-heterozygous knockout mice
24 weeks after H. pylori inoculation, suggesting that both ap-
optosis and proliferation are independent of a deficiency of 1
p53 allele [48]. However, functional studies are necessary to
elucidate the potential role that MIF plays in the regulation of
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H. pylori–induced apoptosis and proliferation, especially in the
late stage of gastric carcinogenesis.
In conclusion, H. pylori infection stimulates the expression
of both MIF protein and MIF mRNA, in both gastric epithelial
and inflammatory cells. Thus, MIF, along with other cytokines,
may play a significant role in gastric inflammation related to
H. pylori infection.
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